MYC and melanoma: Inhibition of polyamine biosynthesis, EIF5A hypusination, or c-Myc suppressed vemurafenib resistance in melanoma cell line models with either acquired or intrinsic resistance against BRAF inhibitors both in vitro and in vivo.